0001179110-15-013212.txt : 20150910 0001179110-15-013212.hdr.sgml : 20150910 20150910165520 ACCESSION NUMBER: 0001179110-15-013212 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20150908 FILED AS OF DATE: 20150910 DATE AS OF CHANGE: 20150910 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ACCELERON PHARMA INC CENTRAL INDEX KEY: 0001280600 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 128 SYDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617-649-9200 MAIL ADDRESS: STREET 1: 128 SYDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: MCLAUGHLIN KEVIN F CENTRAL INDEX KEY: 0001214938 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36065 FILM NUMBER: 151101667 MAIL ADDRESS: STREET 1: C/O ACCELERON PHARMA INC. STREET 2: 128 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 4 1 edgar.xml FORM 4 - X0306 4 2015-09-08 0 0001280600 ACCELERON PHARMA INC XLRN 0001214938 MCLAUGHLIN KEVIN F 128 SIDNEY STREET CAMBRIDGE MA 02139 0 1 0 0 SVP, CFO and Treasurer Common Stock 2015-09-08 4 M 0 5000 3.88 A 45000 D Common Stock 2015-09-08 4 S 0 1207 29.11 D 43793 D Common Stock 2015-09-08 4 S 0 2500 30.22 D 41293 D Common Stock 2015-09-08 4 S 0 1293 31.07 D 40000 D Common Stock 2015-09-08 4 M 0 1500 3.88 A 41500 D Common Stock 2015-09-08 4 S 0 600 29.39 D 40900 D Common Stock 2015-09-08 4 S 0 724 30.45 D 40176 D Common Stock 2015-09-08 4 S 0 176 31.16 D 40000 D Option to Purchase Common Stock 3.88 2015-09-08 4 M 0 5000 0 D 2020-12-02 Common Stock 5000 37251 D Option to Purchase Common Stock 3.88 2015-09-08 4 M 0 1500 0 D 2020-12-02 Common Stock 1500 35751 D The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.73 to $29.69, inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.79 to $30.78, inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.82 to $31.23, inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (4) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.94 to $29.88, inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (5) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.03 to $30.98, inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (6) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.11 to $31.23, inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (7) to this Form 4. The options of registrant's common stock vested as to 25% of the shares on the first anniversary of the grant and in equal installments quarterly thereafter. /s/ John D. Quisel, as attorney-in-fact for Kevin F. McLaughlin 2015-09-10